Greg Walden
Showing 1–3 of 3 transcripts.
- Milken Institute42 min
Walking the Drug-Pricing Tightrope: Fostering Innovation While Maintaining Affordability
Dan Diamond, Matthew Eyles, Dan Leonard, Mark McClellan, Seema Verma, Greg Walden, Matt Iles
Moderated by Dan Diamond, a panel comprising Seema Verma, Matt Iles, Dan Leonard, and Mark McClellan examined the unsustainability of U.S. drug spending and the urgent need for bipartisan legislation to address the "gross-to-net" price bubble and the rising cost of ultra-high therapies. While the group agreed that current payment models create perverse incentives for manufacturers of legacy drugs and antimicrobials, they diverged on solutions, with CMS advocating for private sector competition and industry representatives emphasizing the risks of government price-setting on research and development. The discussion concluded that structural reforms, including value-based arrangements and targeted regulatory changes to Medicaid Best Price rules, are essential to align reimbursement with modern cure cycles before the projected 2026 spending crisis forces administrative intervention.
- a16z17 min
a16z Podcast | Innovation and Regulation -- What Happens When Policy Lags Behind Technology?
Fred Upton, Greg Walden, Michael Copeland, Sonal
The House Energy and Commerce Committee, led by Chairman Fred Upton and Subcommittee Chair Greg Walden, is driving legislative and regulatory reforms to modernize telecommunications and accelerate medical innovation through the bipartisan 21st Century Cures Act. These initiatives prioritize deregulation and market forces to resolve legacy framework bottlenecks, while securing a projected $35 billion to $70 billion in spectrum auction revenue to fund public safety networks and NIH research. By streamlining FDA approval processes and establishing a $2 billion annual research funding stream, the committee aims to reverse the overseas shift in venture capital investment and ensure U.S. leadership in life-saving technologies.
- Milken Institute1h 4m
Combatting the Crisis of Opioids
Sabrina Spitaletta, Alan M. Muney, Joe Smyser, Nora Volkow, Greg Walden, James A. Winnefeld, Jr.
The opioid crisis, driven by initial clinical overconfidence and evolving through three waves of pharmaceuticals, heroin, and synthetic fentanyls, has caused fatalities to surge from hundreds to 20,000 annually. Admiral Winnefeld and legislative bodies are responding with a seven-line strategic framework that prioritizes treating addiction as a chronic disease through prevention, expanded access to Medication-Assisted Treatment, and federal investigations into pharmaceutical diversion in states like West Virginia. Industry stakeholders and policymakers are simultaneously shifting from punitive measures to public health models by updating prescription monitoring laws, integrating telemedicine, and adopting language that reduces stigma to improve treatment outcomes.